Effects of novel HDAC inhibitors on urothelial carcinoma cells

BACKGROUND: Histone deacetylase inhibitors (HDACi) are promising anti-cancer drugs that could also be employed for urothelial carcinoma (UC) therapy. It is unclear, however, whether inhibition of all 11 zinc-dependent HDACs or of individual enzymes is more efficacious and specific. Here, we investig...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Clin Epigenetics
Autori principali: Kaletsch, Aline, Pinkerneil, Maria, Hoffmann, Michèle J., Jaguva Vasudevan, Ananda A., Wang, Chenyin, Hansen, Finn K., Wiek, Constanze, Hanenberg, Helmut, Gertzen, Christoph, Gohlke, Holger, Kassack, Matthias U., Kurz, Thomas, Schulz, Wolfgang A., Niegisch, Günter
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2018
Soggetti:
Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6069857/
https://ncbi.nlm.nih.gov/pubmed/30064501
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13148-018-0531-y
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi